Regeneron Pharmaceuticals Inc

$ 333.34 -9.63 (-2.81%)
Volume: 1,920,372 Avg Vol (1m): 736,032
Market Cap $: 36.43 Bil Enterprise Value $: 34.33 Bil
P/E (TTM): 15.65 P/B: 4.15
Earnings Power Value 97.68
Net Current Asset Value 31.84
Tangible Book 80.34
Projected FCF 175.85
Median P/S Value 575.9
Graham Number 196.22
Peter Lynch Value 532.5
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 8/10

Current vs industry vs history
Cash-to-Debt 3.97
Equity-to-Asset 0.75
Debt-to-Equity 0.08
Debt-to-EBITDA 0.26
Interest Coverage 89.87
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.78
DISTRESS
GREY
SAFE
Beneish M-Score -2.24
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 39.99%
WACC 9.26%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 37.77
Net Margin % 36.42
ROE % 33.46
ROA % 24.14
ROC (Joel Greenblatt) % 59.04
3-Year Total Revenue Growth Rate 17.80
3-Year Total EBITDA Growth Rate 27.60
3-Year EPS w/o NRI Growth Rate 56.80

» REGN's 30-Y Financials

Financials (Next Earnings Date: 2019-05-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:REGN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XKRX:068270 XKRX:207940 NAS:VRTX NAS:ALXN HKSE:01177 LSE:SHP XMCE:GRF.P NAS:BMRN XBRU:UCB NAS:NKTR OCSE:NZYM B NAS:INCY OCSE:GEN NAS:BIVV HKSE:02269 NAS:JUNO NAS:ALNY NAS:BGNE NAS:JAZZ NAS:BIIB
Traded in other countries RGO.Germany 0R2M.UK
Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Ratios

Current vs industry vs history
PE Ratio (TTM) 15.65
Forward PE Ratio 14.37
N/A
PE Ratio without NRI 15.65
Price-to-Owner-Earnings 27.36
PB Ratio 4.15
PS Ratio 5.70
Price-to-Free-Cash-Flow 21.12
Price-to-Operating-Cash-Flow 17.43
EV-to-EBIT 13.30
EV-to-EBITDA 12.57
EV-to-Revenue 5.11
PEG Ratio 0.53
Shiller PE Ratio 60.36
Current Ratio 4.47
Quick Ratio 3.67
Days Inventory 784.65
Days Sales Outstanding 122.01
Days Payable 183.47

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.40

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.15
Price-to-Projected-FCF 1.90
Price-to-Median-PS-Value 0.58
Price-to-Peter-Lynch-Fair-Value 0.63
Price-to-Graham-Number 1.70
Earnings Yield (Joel Greenblatt) % 7.52
Forward Rate of Return (Yacktman) % 22.54

More Statistics

Revenue (TTM) (Mil) $ 6,710.8
EPS (TTM) $ 21.3
Beta 1.13
Volatility % 33.7
52-Week Range $ 281.89 - 442
Shares Outstanding (Mil) 109.28

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N